Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-25 14:58 | Swedish | 10.0 KB | |||
| 2025-11-24 17:30 |
Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S und…
|
English | 71.0 KB | ||
| 2025-11-24 17:30 |
Xbrane Biopharma beslutar om emission av 420 517 teckningsoptioner till Fenja C…
|
Swedish | 62.3 KB | ||
| 2025-11-19 08:00 |
XBRANE UPPDATERAR TIDPLAN FÖR ÅTERINSÄNDNING AV BLA FÖR SIN RANIBIZUMAB-BIOSIMI…
|
Swedish | 70.3 KB | ||
| 2025-11-19 08:00 |
XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIM…
|
English | 70.1 KB | ||
| 2025-11-05 10:52 | Swedish | 10.0 KB | |||
| 2025-11-03 08:35 |
ANTALET AKTIER OCH RÖSTER I XBRANE HAR FÖRÄNDRATS TILL FÖLJD AV TIDIGARE OFFENT…
|
Swedish | 67.6 KB | ||
| 2025-11-03 08:35 |
THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOU…
|
English | 67.1 KB | ||
| 2025-10-24 08:00 | Swedish | 859.8 KB | |||
| 2025-10-24 08:00 | English | 855.9 KB | |||
| 2025-10-20 08:00 |
XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE
|
English | 60.9 KB | ||
| 2025-10-20 08:00 |
XBRANE BIOPHARMA PRESENTERAR VALBEREDNINGEN
|
Swedish | 60.3 KB | ||
| 2025-10-19 20:00 |
Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar c…
|
English | 69.0 KB | ||
| 2025-10-19 20:00 |
Xbrane ger regulatorisk uppdatering om FDA:s granskning av dess ranibizumab-bio…
|
Swedish | 68.9 KB | ||
| 2025-10-16 18:05 |
Xbrane Biopharma ingår villkorad finansieringslösning med Fenja Capital II A/S
|
Swedish | 70.7 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
